NOV (NOV)
(Delayed Data from NYSE)
$18.02 USD
-0.48 (-2.59%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $18.03 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth A Momentum B VGM
Price, Consensus and EPS Surprise
NOV 18.02 -0.48(-2.59%)
Will NOV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NOV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NOV
Nov Inc. (NOV) is a Top-Ranked Value Stock: Should You Buy?
Nov Inc. (NOV) is a Top-Ranked Value Stock: Should You Buy?
NOV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Nov Inc. (NOV) is a Top Momentum Stock for the Long-Term
Why Nov Inc. (NOV) is a Top Momentum Stock for the Long-Term
Is John Hancock Multifactor Small Cap ETF (JHSC) a Strong ETF Right Now?
Other News for NOV
UBS Sticks to Its Hold Rating for Novo Nordisk (0QIU)
J.P. Morgan Remains a Buy on Novo Nordisk (0QIU)
Novo Nordisk’s Strategic Expansion and Innovation in the Obesity Metabolic Space Affirms Buy Rating
Deutsche Numis Sticks to Its Buy Rating for Novo Nordisk (0QIU)
Jefferies Keeps Their Sell Rating on Novo Nordisk (0QIU)